Biomedical Innovation for Facial Bone Reconstruction in Oncology: BIOFACE PASS a Medico-economic Study Describing the Standard Pathway of Patients Treated by Free Bone Flap
Launched by UNIVERSITY HOSPITAL, TOULOUSE · Jan 10, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The BIOFACE PASS trial is a study aimed at understanding how patients with head and neck cancers are treated when they need surgery to reconstruct facial bones. Specifically, it focuses on patients who have oral cavity or upper throat cancers and require a special type of surgery called mandibulectomy or segmental maxillectomy, which involves removing parts of the jaw or upper jaw. The study will look at the standard care process for these patients, particularly those who will receive a "free bone flap" for reconstruction, which is a method where a piece of bone is taken from another part of the body to rebuild the facial structure.
To be eligible for this trial, patients must be at least 18 years old and diagnosed with advanced stage head and neck cancer that can be treated with surgery. They must also be part of the French Social Security system and give their consent to participate. However, certain factors may exclude someone from participating, such as having previous radiation treatment or specific health issues that could complicate the surgery. While the study is not yet recruiting participants, it aims to provide valuable insights into the treatment pathway for those facing significant facial reconstruction after cancer surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient with oral cavity cancer or maxillary and/or oropharynx cancer
- • Eligible for treatment by surgery requiring a mandibulectomy or segmental maxillectomy and having a free bone flap for facial reconstruction.
- • Patient whose disease is classified Stage cT4a, N0 to N3, M0
- • Treatment with a feasible curative aim (no contraindication to optimal treatment such as surgery or chemotherapy at a curative dose)
- • Age greater than or equal to 18 years
- • Patient affiliated to a Social Security scheme in France
- • Patient having given written informed consent
- Non-inclusion Criteria:
- • Patient having any situation considered by the doctor as a reason for non-inclusion such as stenosis of the leg tripod not allowing reconstruction by fibula, one or more comorbidity(s) not allowing reconstruction by free bone flap or making this reconstruction too much risk
- • Patient having had previous radiotherapy
- • Patient with severe coagulation disorders
- • Patients deprived of liberty or under legal protection regime (curatorship and guardianship, safeguard of justice)
About University Hospital, Toulouse
The University Hospital of Toulouse is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care, the hospital integrates cutting-edge scientific inquiry with comprehensive clinical services. Its multidisciplinary team of healthcare professionals collaborates with renowned researchers to facilitate pioneering studies across various medical fields, aiming to enhance treatment options and improve patient outcomes. As a prominent institution in the region, the University Hospital of Toulouse is committed to fostering an environment of excellence in both education and research within the healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nice, , France
Villejuif, , France
Lille, , France
Rouen, , France
Toulouse, , France
Nantes, , France
Lyon, , France
Montpellier, , France
Amiens, , France
Patients applied
Trial Officials
Agnès DUPRET-BORIES
Principal Investigator
University Hospital, Toulouse
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported